ArticleJACC. Case reports2026
TEER Beyond Contraindication: Resolving Recurrent Cerebral Infarction in a Patient With Degenerative Mitral Regurgitation.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Partnerships for Progress: Another Year of China Valve.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDegenerative mitral regurgitation is a common valvular heart disease, with transcatheter edge-to-edge repair an alternative option for high-risk patients. Nonbacterial thrombotic endocarditis, a rare condition with sterile valvular excrescences, often causes cerebrovascular embolism and is thought to be the contraindication to transcatheter edge-to-edge repair. CASE SUMMARY: A 52-year-old man with multiple comorbidities presented to the hospital with recurrent cerebral infarctions, massive mitral regurgitation and nonbacterial thrombotic endocarditis. Transcatheter edge-to-edge repair and carotid embolic protection device implantation were performed to ameliorate mitral regurgitation, avoid the recurrence of cerebral embolism and delay the time for surgical valve replacement. DISCUSSION: The patient's history of antineutrophil cytoplasmic antibody-associated vasculitis, nephritis, and glucocorticoid use made surgical treatment risky. Transcatheter edge-to-edge repair is feasible for severe degenerative mitral regurgitation with nonbacterial thrombotic endocarditis, especially with carotid protection, which reduces embolism risk and postpones valve replacement. TAKE-HOME MESSAGE: This case demonstrates the feasibility of transcatheter edge-to-edge repair with concurrent nonbacterial thrombotic endocarditis and recurrent cerebral infarction when paired with carotid embolic protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.